SCI时时刷

search
+
Downregulation of N4-acetylcytidine modification in myeloid cells attenuates immunotherapy and exacerbates hepatocellular carcinoma progression
Downregulation of N4-acetylcytidine modification in myeloid cells attenuates immunotherapy and exacerbates hepatocellular carcinoma progression
N4-acetylcytidine (ac4C) is a conserved and abundant mRNA modification that controls protein expression by affecting trans...
Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal cancer – possible implications for immunotherapy
Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal cancer – possible implications for immunotherapy
The immune response has important clinical value in colorectal cancer (CRC) in both prognosis and response to immunotherap...
Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis
Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis
Risk-reducing mastectomy (RRM) is offered to women with a BRCA1 or BRCA2 pathogenic variant, however, there are limited da...
Aspirin and cancer treatment: systematic reviews and meta-analyses of evidence: for and against
Aspirin as a possible treatment of cancer has been of increasing interest for over 50 years, but the balance of the risks ...
Health benefits and harms of mammography screening in older women (75+ years)—a systematic review
Health benefits and harms of mammography screening in older women (75+ years)—a systematic review
There is little evidence on the balance between potential benefits and harms of mammography screening in women 75 years an...
Low-dose metronomic cisplatin as an antiangiogenic and anti-inflammatory strategy for cancer
Low-dose metronomic cisplatin as an antiangiogenic and anti-inflammatory strategy for cancer
Conventional chemotherapy is based on the maximum tolerated dose (MTD) and requires treatment-free intervals to restore no...
Multivitamin use and all-cause and cause-specific mortality in cancer survivors
Multivitamin use and all-cause and cause-specific mortality in cancer survivors
Despite no sufficient evidence on benefits and harms of multivitamin use, cancer survivors use multivitamins as a self-car...
Educational attainment in survivors of childhood cancer in Denmark, Finland, and Sweden
Educational attainment in survivors of childhood cancer in Denmark, Finland, and Sweden
Survivors of childhood cancer may face difficulties at school. We investigated whether childhood cancer affects attainment...
Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial
Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial
FOLFOXIRI plus bevacizumab has demonstrated benefits for metastatic colorectal cancer (mCRC) patients. However, challenges...
Long-term outcomes of neoadjuvant immunotherapy plus chemotherapy in patients with early-stage triple-negative breast cancer: an extracted individual patient data and trial-level meta-analysis
Long-term outcomes of neoadjuvant immunotherapy plus chemotherapy in patients with early-stage triple-negative breast cancer: an extracted individual patient data and trial-level meta-analysis
Neoadjuvant immunotherapy (nIO) has emerged as a treatment option for stage II–III triple-negative breast cancer (TN...
EEF1A2 promotes HIF1A mediated breast cancer angiogenesis in normoxia and participates in a positive feedback loop with HIF1A in hypoxia
EEF1A2 promotes HIF1A mediated breast cancer angiogenesis in normoxia and participates in a positive feedback loop with HIF1A in hypoxia
The eukaryotic elongation factor, EEF1A2, has been identified as an oncogene in various solid tumors. Here, we have identi...
Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy
Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy
High rates of failure, exorbitant costs, and the sluggish pace of new drug discovery and development have led to a growing...
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)
Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)
CC-115, a dual mTORC1/2 and DNA-PK inhibitor, has promising antitumour activity when combined with androgen receptor (AR) ...
APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells
APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells
Aberrant WNT/β-catenin signaling drives carcinogenesis. Tankyrases poly(ADP-ribosyl)ate and destabilize AXINs, β...
Comment on “Development and validation of a multivariable model for prediction of malignant transformation and recurrence of oral epithelial dysplasia”
Mahmood H, Shephard A, Hankinson P, Bradburn M, Araujo ALD, Santos-Silva AR, et al. Development and validation of a multiv...
Dexamethasone-sparing on days 2–4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)
Dexamethasone-sparing on days 2–4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial)
This study evaluated the non-inferiority of dexamethasone (DEX) on day 1, with sparing on days 2–4 in cisplatin-base...
Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer
Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer
Circulating tumour cells (CTCs), circulating tumour DNA (ctDNA), and extracellular vesicles (EVs) are minimally invasive l...
Accuracy of HPV E6/E7 oncoprotein tests to detect high-grade cervical lesions: a systematic literature review and meta-analysis
Accuracy of HPV E6/E7 oncoprotein tests to detect high-grade cervical lesions: a systematic literature review and meta-analysis
Cervical carcinogenesis is mediated by the HPV-E6 and E7 oncoproteins, considered as biomarkers usable in managing screen-...
Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy
Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy
Luminal breast cancers with high proliferation (MKShi) and low ER-related signalling (ERSlo) have a poor prognosis. We inv...
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies
Resistance to osimertinib in advanced EGFR-mutated non-small cell lung cancer (NSCLC) constitutes a significant challenge ...
Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with liver metastases
Nearly one-fifth of patients with non-small cell Lung Cancer (NSCLC) will develop liver metastases (LMs), and the overall ...
Acquired copy number variation in prostate tumours: a review of common somatic copy number alterations, how they are formed and their clinical utility
Acquired copy number variation in prostate tumours: a review of common somatic copy number alterations, how they are formed and their clinical utility
Prostate cancer is one of the most commonly diagnosed cancers in men and unfortunately, disease will progress in up to a t...
Integrating a microRNA signature as a liquid biopsy-based tool for the early diagnosis and prediction of potential therapeutic targets in pancreatic cancer
Integrating a microRNA signature as a liquid biopsy-based tool for the early diagnosis and prediction of potential therapeutic targets in pancreatic cancer
Pancreatic cancer is a highly aggressive cancer, and early diagnosis significantly improves patient prognosis due to the e...
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN
Apalutamide plus androgen-deprivation therapy (ADT) improved outcomes in metastatic castration-sensitive prostate cancer (...
Enlarged tumour-draining lymph node with immune-activated profile predict favourable survival in non-metastatic colorectal cancer
Enlarged tumour-draining lymph node with immune-activated profile predict favourable survival in non-metastatic colorectal cancer
The tumour-draining lymph node (TDLN) plays a pivotal role in the suppression of malignant tumour, however, the immunologi...
Correction: Inequalities in treatment among patients with colon and rectal cancer: a multistate survival model using data from England National Cancer Registry 2012–2016
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which...
Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor
Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor
Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer, arising from resistance to androgen-depriv...
Supporting gut health with medicinal cannabis in people with advanced cancer: potential benefits and challenges
Supporting gut health with medicinal cannabis in people with advanced cancer: potential benefits and challenges
The side effects of cancer therapy continue to cause significant health and cost burden to the patient, their friends and ...
The novel CDK9 inhibitor, XPW1, alone and in combination with BRD4 inhibitor JQ1, for the treatment of clear cell renal cell carcinoma
The novel CDK9 inhibitor, XPW1, alone and in combination with BRD4 inhibitor JQ1, for the treatment of clear cell renal cell carcinoma
Clear cell renal cell carcinoma (ccRCC) is a highly lethal malignancy with few therapeutic options. Cyclin‑dependent...
Body composition and cancer survival: a narrative review
Body composition and cancer survival: a narrative review
Interest in understanding the relationship between body composition and cancer survival has remained strong for decades, w...
阅读更多
format_indent_increase